PLEKHA6

Summary

PLEKHA6 (pleckstrin homology domain containing A6, HGNC:17053) is a protein-coding gene on chromosome 1q32.1, encoding Pleckstrin homology domain-containing family A member 6 (Q9Y2H5).

At a glance

• Gene–disease (curated): schizophrenia (No Known Disease Relationship, GenCC)
• GWAS associations: 19
• Clinical variants (ClinVar): 232 total
• MANE Select transcript: NM_014935

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17053
Approved symbol	PLEKHA6
Name	pleckstrin homology domain containing A6
Location	1q32.1
Locus type	gene with protein product
Status	Approved
Aliases	PEPP3, KIAA0969
Ensembl gene	ENSG00000143850
Ensembl biotype	protein_coding
OMIM	607771
Entrez	22874

Gene structure

Transcript identifiers

Ensembl transcripts: 65 — 63 protein_coding, 1 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000272203, ENST00000414478, ENST00000485632, ENST00000564627, ENST00000637508, ENST00000672625, ENST00000713653, ENST00000713654, ENST00000713655, ENST00000713656, ENST00000713657, ENST00000851083, ENST00000859254, ENST00000859255, ENST00000859256, ENST00000859257, ENST00000859258, ENST00000859259, ENST00000859260, ENST00000859261, ENST00000859262, ENST00000859263, ENST00000859264, ENST00000859265, ENST00000859266, ENST00000859267, ENST00000859268, ENST00000859269, ENST00000859270, ENST00000859271, ENST00000859272, ENST00000859273, ENST00000859274, ENST00000859275, ENST00000859276, ENST00000859277, ENST00000859278, ENST00000859279, ENST00000859280, ENST00000859281, ENST00000859282, ENST00000859283, ENST00000859284, ENST00000859285, ENST00000859286, ENST00000859287, ENST00000859288, ENST00000859289, ENST00000859290, ENST00000859291, ENST00000859292, ENST00000859293, ENST00000859294, ENST00000859295, ENST00000859296, ENST00000859297, ENST00000859298, ENST00000921178, ENST00000921179, ENST00000921180, ENST00000921181, ENST00000921182, ENST00000943169, ENST00000943170, ENST00000943171

RefSeq mRNA: 1 — MANE Select: NM_014935 NM_014935

CCDS: CCDS1444

Canonical transcript exons

ENST00000272203 — 23 exons

Exon	Start	End
ENSE00000962329	204268208	204268312
ENSE00000962330	204267475	204267547
ENSE00000962331	204264942	204265042
ENSE00000962332	204261306	204261448
ENSE00000962333	204259258	204259740
ENSE00000962334	204257353	204257869
ENSE00000962335	204250546	204250614
ENSE00000962336	204249184	204249264
ENSE00000962337	204248821	204248970
ENSE00000962338	204247365	204247460
ENSE00000962339	204245615	204245726
ENSE00000962340	204244864	204245003
ENSE00000962341	204241685	204241814
ENSE00000962342	204241375	204241481
ENSE00001039735	204228937	204229104
ENSE00001039739	204228728	204228861
ENSE00001039740	204230413	204230586
ENSE00001039741	204228083	204228228
ENSE00001125867	204223462	204223585
ENSE00001125876	204273626	204273740
ENSE00001365727	204274729	204274809
ENSE00003696537	204218853	204222779
ENSE00003847625	204359694	204359929

Expression profiles

Bgee: expression breadth ubiquitous, 244 present calls, max score 92.70.

FANTOM5 (CAGE): breadth broad, TPM avg 7.3004 / max 327.9522, expressed in 746 samples.

FANTOM5 promoters (12 alternative TSS)

Promoter ID	TPM avg	Samples expressed
16900	3.6731	332
16907	2.1127	275
16888	0.5395	247
16889	0.4453	154
16902	0.1441	65
16887	0.1108	38
16899	0.1096	57
16901	0.0640	40
16890	0.0494	16
16906	0.0254	8

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
C1 segment of cervical spinal cord	UBERON:0006469	92.70	gold quality
Brodmann (1909) area 23	UBERON:0013554	92.51	gold quality
right hemisphere of cerebellum	UBERON:0014890	91.98	gold quality
rectum	UBERON:0001052	91.75	gold quality
middle temporal gyrus	UBERON:0002771	91.74	gold quality
mucosa of transverse colon	UBERON:0004991	91.71	gold quality
endothelial cell	CL:0000115	91.36	gold quality
primary visual cortex	UBERON:0002436	91.32	gold quality
lower esophagus mucosa	UBERON:0035834	91.25	gold quality
right frontal lobe	UBERON:0002810	91.15	gold quality
cerebellar hemisphere	UBERON:0002245	91.11	gold quality
cerebellar cortex	UBERON:0002129	90.94	gold quality
apex of heart	UBERON:0002098	90.84	gold quality
pituitary gland	UBERON:0000007	90.64	gold quality
spinal cord	UBERON:0002240	90.50	gold quality
right lobe of liver	UBERON:0001114	90.26	gold quality
adenohypophysis	UBERON:0002196	90.01	gold quality
right atrium auricular region	UBERON:0006631	89.40	gold quality
metanephros cortex	UBERON:0010533	89.15	gold quality
nucleus accumbens	UBERON:0001882	88.78	gold quality
cerebellum	UBERON:0002037	88.76	gold quality
lateral nuclear group of thalamus	UBERON:0002736	88.76	gold quality
transverse colon	UBERON:0001157	88.29	gold quality
occipital lobe	UBERON:0002021	88.18	gold quality
prefrontal cortex	UBERON:0000451	87.87	gold quality
caudate nucleus	UBERON:0001873	87.71	gold quality
cardiac atrium	UBERON:0002081	87.71	gold quality
body of stomach	UBERON:0001161	87.68	gold quality
stomach	UBERON:0000945	87.32	gold quality
islet of Langerhans	UBERON:0000006	87.07	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-GEOD-83139	yes	8.13
E-ANND-3	yes	4.51

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

133 targeting PLEKHA6, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-5193	100.00	67.26	1744
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-LET-7F-2-3P	99.98	70.98	2588
HSA-MIR-1185-1-3P	99.98	71.04	2593
HSA-MIR-1185-2-3P	99.98	71.04	2593
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-381-3P	99.93	71.87	2854
HSA-MIR-300	99.92	71.76	2856
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-MIR-6715A-3P	99.83	68.05	1473

Literature-anchored findings (GeneRIF, showing 2)

• This study demonistrated that PLEKHA6 polymorphisms are associated with psychopathology and response to treatment in schizophrenic patients. (PMID:24576533)
• PLEKHA5, PLEKHA6, and PLEKHA7 bind to PDZD11 to target the Menkes ATPase ATP7A to the cell periphery and regulate copper homeostasis. (PMID:34613798)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	plekha6	ENSDARG00000020328
mus_musculus	Plekha6	ENSMUSG00000041757
rattus_norvegicus	Plekha6	ENSRNOG00000002907

Paralogs (3): PLEKHA5 (ENSG00000052126), PLEKHA4 (ENSG00000105559), PLEKHA7 (ENSG00000166689)

Protein

Protein identifiers

Pleckstrin homology domain-containing family A member 6 — Q9Y2H5 (reviewed: Q9Y2H5)

Alternative names: Phosphoinositol 3-phosphate-binding protein 3

All UniProt accessions (6): Q9Y2H5, A0A1B0GUN5, A0A1B0GW03, A0A5F9ZH45, A0AAQ5BGL2, Q5VTI5

UniProt curated annotations — full annotation on UniProt →

Tissue specificity. Highly expressed in heart, kidney and throughout the brain.

RefSeq proteins (1): NP_055750* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001849	PH_domain	Domain
IPR011993	PH-like_dom_sf	Homologous_superfamily
IPR040392	PKHA4-7_PH	Domain
IPR057971	PKHA4-7_TBCA	Domain

Pfam: PF00169, PF25541

UniProt features (54 total): modified residue 22, compositionally biased region 10, strand 9, region of interest 7, sequence variant 2, chain 1, domain 1, turn 1, helix 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
2D9Y	SOLUTION NMR
2YRY	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9Y2H5-F1	57.15	0.18

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (22): 247, 251, 314, 459, 461, 472, 492, 591, 744, 777, 784, 801, 848, 854, 867, 920, 940, 1015, 1017, 1020 …

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-1660499	Synthesis of PIPs at the plasma membrane

MSigDB gene sets: 176 (showing top): GCANCTGNY_MYOD_Q6, MAZ_Q6, MEF2_02, CHX10_01, CAGCTG_AP4_Q5, DOANE_RESPONSE_TO_ANDROGEN_DN, USF_01, TGIF_01, OCT1_07, AFP1_Q6, USF_02, AML1_01, CART1_01, CCCNNGGGAR_OLF1_01, CTAWWWATA_RSRFC4_Q2

GO Biological Process (0):

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (0):

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
PI Metabolism	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	1

Protein interactions and networks

STRING

456 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PLEKHA6	PLEK2	Q9NYT0	651
PLEKHA6	PLEK	P08567	648
PLEKHA6	GOLT1A	Q6ZVE7	572
PLEKHA6	ETNK2	Q9NVF9	477
PLEKHA6	NTRK1	P04629	464
PLEKHA6	OR2G6	Q5TZ20	448
PLEKHA6	CTNNB1	P35222	386
PLEKHA6	PLEKHA4	Q9H4M7	376
PLEKHA6	SCFD2	Q8WU76	372
PLEKHA6	SCYL3	Q8IZE3	365
PLEKHA6	IRGQ	Q8WZA9	363
PLEKHA6	LANCL2	Q9NS86	348
PLEKHA6	SOX13	Q9UN79	348
PLEKHA6	CLEC12B	Q2HXU8	340
PLEKHA6	PIK3C2B	O00750	337

IntAct

17 interactions, top by confidence:

A	B	Type	Score
UBE2Z	PLEKHA6	psi-mi:“MI:0915”(physical association)	0.560
PFDN1	ARHGAP32	psi-mi:“MI:0914”(association)	0.530
Xpo1	IFT56	psi-mi:“MI:0914”(association)	0.350
CFTR		psi-mi:“MI:0914”(association)	0.350
MYBPHL	CASK	psi-mi:“MI:0914”(association)	0.350
MAGI1	CIT	psi-mi:“MI:0914”(association)	0.350
RIMS1	KIF2A	psi-mi:“MI:0914”(association)	0.350
PLEKHA6	KCTD9	psi-mi:“MI:0914”(association)	0.350
ARMC8	VWA8	psi-mi:“MI:0914”(association)	0.350
PPP2R2B	ARHGAP10	psi-mi:“MI:0914”(association)	0.350
	NFIB	psi-mi:“MI:0914”(association)	0.350
ORF44	ALYREF	psi-mi:“MI:0914”(association)	0.350
CDH1	ESYT2	psi-mi:“MI:2364”(proximity)	0.270
EPHA1	PLEKHA6	psi-mi:“MI:0915”(physical association)	0.000
UBE2Z	PLEKHA6	psi-mi:“MI:0915”(physical association)	0.000
PLEKHA6	PLEKHA5	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (38): PLEKHA6 (Affinity Capture-MS), PLEKHA6 (Affinity Capture-MS), PLEKHA6 (Affinity Capture-MS), PLEKHA6 (Proximity Label-MS), PLEKHA6 (Affinity Capture-MS), PLEKHA6 (Affinity Capture-RNA), PLEKHA6 (Affinity Capture-MS), PLEKHA6 (Affinity Capture-MS), PLEKHA6 (Affinity Capture-MS), PLEKHA6 (Proximity Label-MS), UBE2Z (Two-hybrid), PLEKHA6 (Affinity Capture-MS), PLEKHA6 (Affinity Capture-MS), PLEKHA6 (Affinity Capture-RNA), PLEKHA6 (Affinity Capture-MS)

ESM2 similar proteins: A0JLT2, A4QNZ7, A5PK23, B1AZP2, F5HSE3, O60293, O75420, O95402, P61129, P78312, P97839, Q03111, Q07FY3, Q08C81, Q08DM1, Q174D3, Q1LVC2, Q32NP7, Q3T044, Q4G0F8, Q5EAY2, Q5F368, Q5R8Q8, Q5U2R6, Q6DD45, Q6DRL8, Q6PEI3, Q7TN02, Q80Z38, Q8C1B1, Q8C1S0, Q8CFT2, Q8CGI1, Q8IVL1, Q8K4J6, Q90YL3, Q90YY5, Q969V6, Q96A73, Q99MR1

Diamond homologs: B6RSP1, D3ZL52, G9CGD6, O08967, O43739, P54644, P60669, P97434, P97696, Q3UIL6, Q5DU31, Q6IQ23, Q6WCQ1, Q6ZNL6, Q7TQG1, Q80UZ0, Q80VL0, Q80YA9, Q86IV4, Q8BH49, Q8C4V1, Q8N264, Q8N4B1, Q8VC98, Q8WWN9, Q8WXI2, Q99KW3, Q9ERE6, Q9ERS5, Q9H4M7, Q9HAU0, Q9HB19, Q9Y2H5, Q9Z1T4, A2A2Y4, A2AD83, A2ALK8, B2RYE5, F1LYQ8, F1P065

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

232 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	196
Likely benign	8
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

4785 predictions. Top by Δscore:

Variant	Effect	Δscore
1:204228226:ATA:A	acceptor_gain	1.0000
1:204228227:TA:T	acceptor_gain	1.0000
1:204228229:C:CC	acceptor_gain	1.0000
1:204228238:C:CT	acceptor_gain	1.0000
1:204228240:C:CT	acceptor_gain	1.0000
1:204228827:C:CT	acceptor_gain	1.0000
1:204228932:CTCA:C	donor_loss	1.0000
1:204228933:TCA:T	donor_loss	1.0000
1:204228934:CACC:C	donor_loss	1.0000
1:204228935:A:AC	donor_gain	1.0000
1:204228935:AC:A	donor_gain	1.0000
1:204228935:ACCT:A	donor_gain	1.0000
1:204228935:ACCTC:A	donor_gain	1.0000
1:204228936:C:CA	donor_gain	1.0000
1:204228936:CC:C	donor_gain	1.0000
1:204228936:CCT:C	donor_gain	1.0000
1:204228936:CCTC:C	donor_gain	1.0000
1:204228936:CCTCC:C	donor_gain	1.0000
1:204228938:T:TA	donor_gain	1.0000
1:204229102:CAC:C	acceptor_gain	1.0000
1:204230412:CCA:C	donor_gain	1.0000
1:204241482:C:CC	acceptor_gain	1.0000
1:204245611:CCA:C	donor_loss	1.0000
1:204245612:CAC:C	donor_loss	1.0000
1:204245613:A:AC	donor_gain	1.0000
1:204245613:ACCTC:A	donor_loss	1.0000
1:204245614:C:CC	donor_gain	1.0000
1:204245614:C:G	donor_loss	1.0000
1:204245614:CCT:C	donor_gain	1.0000
1:204245657:T:TA	donor_gain	1.0000

AlphaMissense

6836 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:204248858:A:G	L596P	1.000
1:204249197:A:G	L554P	1.000
1:204261385:A:G	W149R	1.000
1:204261385:A:T	W149R	1.000
1:204267526:A:G	W77R	1.000
1:204267526:A:T	W77R	1.000
1:204268211:T:A	K68N	1.000
1:204268211:T:G	K68N	1.000
1:204228743:A:G	L957P	0.999
1:204228752:A:C	I954S	0.999
1:204228752:A:G	I954T	0.999
1:204228752:A:T	I954N	0.999
1:204247393:A:G	L631P	0.999
1:204248829:C:G	A606P	0.999
1:204248837:A:G	L603P	0.999
1:204248963:A:G	L561P	0.999
1:204261383:C:A	W149C	0.999
1:204261383:C:G	W149C	0.999
1:204261417:A:G	F138S	0.999
1:204261424:A:C	Y136D	0.999
1:204264942:C:A	K127N	0.999
1:204264942:C:G	K127N	0.999
1:204264946:A:G	F126S	0.999
1:204264996:G:C	F109L	0.999
1:204264996:G:T	F109L	0.999
1:204264998:A:G	F109L	0.999
1:204265006:A:T	L106H	0.999
1:204265014:G:C	S103R	0.999
1:204265014:G:T	S103R	0.999
1:204265016:T:G	S103R	0.999

dbSNP variants (sampled 300 via entrez): RS1000003862 (1:204302827 T>C), RS1000019186 (1:204302289 A>C), RS1000027982 (1:204264549 A>C), RS1000036931 (1:204349505 C>T), RS1000052285 (1:204345028 T>C), RS1000079950 (1:204247836 T>C), RS1000090892 (1:204265844 A>G,T), RS1000101440 (1:204350864 C>G), RS1000124001 (1:204346112 T>C), RS1000125855 (1:204331805 C>T), RS1000135433 (1:204289242 G>A), RS1000186602 (1:204285173 T>C), RS1000188629 (1:204366685 C>T), RS1000201268 (1:204266964 C>T), RS1000205903 (1:204377046 G>A)

Disease associations

OMIM: gene MIM:607771 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
schizophrenia	No Known Disease Relationship	Unknown

Mondo (1): schizophrenia (MONDO:0005090)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

19 associations (top):

Study	Trait	p-value
GCST001841_11	Palmitoleic acid (16:1n-7) levels	3.000000e-06
GCST001942_20	Prostate cancer	2.000000e-11
GCST004607_208	Plateletcrit	2.000000e-12
GCST006922_4	Regular attendance at a religious group	3.000000e-08
GCST008359_1	Response to cognitive-behavioural therapy in anxiety disorder	7.000000e-07
GCST010796_2654	Electrocardiogram morphology (amplitude at temporal datapoints)	3.000000e-08
GCST010796_2655	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-08
GCST010796_2656	Electrocardiogram morphology (amplitude at temporal datapoints)	1.000000e-08
GCST010796_2657	Electrocardiogram morphology (amplitude at temporal datapoints)	9.000000e-09
GCST012322_13	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	3.000000e-07
GCST90002383_345	Hematocrit	4.000000e-12
GCST90002384_22	Hemoglobin	6.000000e-11
GCST90002388_641	Lymphocyte count	1.000000e-16
GCST90002393_173	Monocyte count	4.000000e-12
GCST90002400_536	Plateletcrit	2.000000e-25
GCST90002402_258	Platelet count	2.000000e-10
GCST90002402_259	Platelet count	5.000000e-23
GCST90002403_58	Red blood cell count	4.000000e-10
GCST90016667_13	Spleen volume	3.000000e-09

EFO canonical traits (12, from GWAS)

EFO ID	Trait name
EFO:0007985	platelet crit
EFO:0009592	social interaction measurement
EFO:0007820	cognitive behavioural therapy
EFO:0004327	electrocardiography
EFO:0004530	triglyceride measurement
EFO:0005658	response to selective serotonin reuptake inhibitor
EFO:0004348	hematocrit
EFO:0004509	hemoglobin measurement
EFO:0004587	lymphocyte count
EFO:0005091	monocyte count
EFO:0004309	platelet count
EFO:0004305	erythrocyte count

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

45 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects expression, decreases expression, affects cotreatment, increases abundance, increases expression	5
Arsenic	decreases expression, affects methylation, increases abundance, increases expression, affects cotreatment	4
Acetaminophen	decreases expression, increases expression	2
Calcitriol	affects cotreatment, increases expression	2
Estradiol	affects cotreatment, decreases expression, increases expression	2
Hydrogen Peroxide	affects expression	2
Tretinoin	increases expression	2
Valproic Acid	increases expression, increases methylation	2
Cadmium Chloride	decreases expression, increases expression	2
aristolochic acid I	increases expression	1
dicrotophos	increases expression	1
propionaldehyde	decreases expression	1
bisphenol A	decreases expression, increases methylation	1
diethyl phthalate	decreases expression, increases abundance	1
sodium arsenate	increases abundance, increases expression	1
2,5,2’,5’-tetrachlorobiphenyl	decreases expression	1
arsenite	affects binding, decreases reaction	1
butyraldehyde	decreases expression	1
manganese chloride	decreases expression, increases abundance, affects cotreatment	1
cupric chloride	decreases expression	1
S-(1,2-dichlorovinyl)cysteine	decreases expression	1
2,3,5-(triglutathion-S-yl)hydroquinone	increases ADP-ribosylation	1
CGP 52608	affects binding, increases reaction	1
monoethyl phthalate	decreases expression, increases abundance	1
theaflavin-3,3’-digallate	affects expression	1
Sunitinib	increases expression	1
Arsenic Trioxide	decreases response to substance	1
Vorinostat	decreases expression	1
Atrazine	decreases expression	1
Benzo(a)pyrene	affects methylation	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00000374	PHASE4	COMPLETED	Treatment for First-Episode Schizophrenia
NCT00001656	PHASE4	COMPLETED	Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders
NCT00007774	PHASE4	COMPLETED	To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia
NCT00014001	PHASE4	COMPLETED	CATIE- Schizophrenia Trial
NCT00018668	PHASE4	COMPLETED	Antipsychotic Response in Schizophrenia
NCT00034801	PHASE4	COMPLETED	Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
NCT00034905	PHASE4	COMPLETED	A Comparison of Seroquel vs. Risperidone in Schizophrenia
NCT00036088	PHASE4	COMPLETED	Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia
NCT00044187	PHASE4	COMPLETED	The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
NCT00044655	PHASE4	COMPLETED	Switching Medication to Treat Schizophrenia
NCT00048828	PHASE4	COMPLETED	Treating Drug-Resistant Childhood Schizophrenia
NCT00053703	PHASE4	COMPLETED	Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)
NCT00056498	PHASE4	COMPLETED	Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine
NCT00061802	PHASE4	COMPLETED	Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder
NCT00080327	PHASE4	COMPLETED	Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
NCT00088049	PHASE4	COMPLETED	Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia
NCT00090012	PHASE4	COMPLETED	Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
NCT00100776	PHASE4	COMPLETED	Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder
NCT00103571	PHASE4	COMPLETED	Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
NCT00108368	PHASE4	COMPLETED	The Effects of Risperidone and Olanzapine on Thinking
NCT00114595	PHASE4	COMPLETED	Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia
NCT00130923	PHASE4	COMPLETED	Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
NCT00137020	PHASE4	COMPLETED	Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder
NCT00140166	PHASE4	COMPLETED	Treatment of Acute Schizophrenia With Vitamin Therapy
NCT00145847	PHASE4	COMPLETED	Naltrexone Treatment of Alcohol Abuse in Schizophrenia
NCT00148564	PHASE4	COMPLETED	Energy Homeostasis Under Treatment With Atypical Antipsychotics
NCT00156715	PHASE4	COMPLETED	Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
NCT00158223	PHASE4	COMPLETED	Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia
NCT00159081	PHASE4	COMPLETED	One Year Drug Treatment in First-Episode Schizophrenia
NCT00159120	PHASE4	COMPLETED	Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia
NCT00159133	PHASE4	COMPLETED	Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia
NCT00159757	PHASE4	TERMINATED	12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients
NCT00167817	PHASE4	COMPLETED	Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study
NCT00169026	PHASE4	TERMINATED	Alcoholism and Schizophrenia: Effects of Clozapine
NCT00169039	PHASE4	TERMINATED	Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia
NCT00169065	PHASE4	COMPLETED	Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia
NCT00169091	PHASE4	TERMINATED	Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia
NCT00176423	PHASE4	COMPLETED	Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia
NCT00176436	PHASE4	COMPLETED	Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients
NCT00177008	PHASE4	COMPLETED	Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety